Uppsala, Sweden – December 12, 2013 – Orexo AB, “Orexo” (OTCQX: ORXOY; NASDAQ
OMX Stockholm: ORX) announces closing of a MSEK 200 (MUSD 30) revolving credit
facility with Danske Bank. MSEK 100 will be available immediately upon closing
and the remaining MSEK 100 when specific Zubsolv® revenue milestones are met.
The facility has a two year tenure with an extension option and the facility
replaces the existing overdraft facility of MSEK 50.

Henrik Juuel, EVP and Chief Financial Officer of Orexo commented: “I am very
pleased that we now have secured the necessary liquidity to support our
commercialization efforts and further development of Zubsolv®. This engagement
underscores the strength of the focused business model that Orexo is operating,
a belief in success for Zubsolv, and marks the establishment of a good
partnership. I am looking very much forward to the cooperation with Danske
Bank”.

For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com

About Orexo AB
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv®, for maintenance
treatment of opioid dependence, in the United States. Zubsolv is a novel
formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and revenue
generating products currently marketed under license in the EU and US. Orexo AB,
with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange,
under the symbol “ORX”, and its American Depositary Receipts (ADRs) trade on the
OTCQX marketplace in the U.S. under the symbol “ORXOY”. The largest shareholders
are Novo A/S and HealthCap.

For information about Orexo AB, please visit www.orexo.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:00 pm CET on December 12,
2013.